Related Experiment Video
Updated: Jun 26, 2026
06:51
Systemic Delivery of MicroRNA Using Recombinant Adeno-associated Virus Serotype 9 to Treat Neuromuscular Diseases in Rodents
Published on: August 10, 2018
Viral agents in neuromuscular pathology
Abhay Kumar Singh1, Yemgadda Goutham Sudhan1, Ramakrisha Ramakrishna1
1Department of Microbiology, School of Life Sciences, Central University of Tamil Nadu, Tiruvarur, India.
International Review of Neurobiology
|May 25, 2025
Summary
Viral infections are increasingly linked to neuromuscular disorders. This overview covers epidemiology, diagnosis, and treatment for conditions like Guillain-Barré syndrome caused by various viruses, including SARS-CoV-2.
Area of Science:
- Neurology
- Virology
- Pathology
Background:
- Viral infections are a growing cause of neuromuscular pathologies.
- Understanding virus-host interactions is crucial for neuromuscular health.
Purpose of the Study:
- To provide a comprehensive overview of virus-induced neuromuscular disorders.
- To integrate evidence on epidemiology, clinical features, diagnosis, treatment, and prevention.
Main Methods:
- Literature review and synthesis of current evidence.
- Integration of global burden data, clinical features, and diagnostic approaches.
- Discussion of therapeutic strategies, rehabilitation, and preventive measures.
Main Results:
- Identified key viruses: enteroviruses, flaviviruses, herpesviruses, and SARS-CoV-2.
- Highlighted spectrum of disorders: Guillain-Barré syndrome, viral myositis, critical illness neuropathy/myopathy.
- Emphasized novel therapies, research needs, and future perspectives.
Conclusions:
- Clinical research and care require understanding virus-neuromuscular system interactions.
- Effective management necessitates integrated approaches to diagnosis, treatment, and prevention.
- Future research should focus on unmet needs in viral neuromuscular disorders.
Keywords:
AxonopathyElectrophysiologyGuillain-Barré syndromeImmunopathogenesisMyositisNeuroimmunologyNeuromuscular junction dysfunctionNeuropathologyNeurotropismViral persistenceMore Related Videos
Related Concept Videos
01:22Myasthenia Gravis ll: Pathophysiology
The disease process of myasthenia gravis begins at the neuromuscular junction, where antibodies attack key proteins needed for muscle activation. This immune reaction weakens signal transmission, leading to the characteristic muscle fatigue and weakness that define the condition.Immune-Mediated DamageIn most individuals, antibodies target acetylcholine receptors (AChRs) on the postsynaptic membrane of muscle cells. By blocking acetylcholine binding, these antibodies prevent the nerve signal...
01:29Neuromuscular Junction And Blockade
The site of chemical communication between a motor neuron and a muscle fiber is called the neuromuscular junction (NMJ). The end of the motor neuron at the NMJ divides into a cluster of synaptic end bulbs. The cytoplasm of these bulbs consists of synaptic vesicles enclosing acetylcholine molecules, the principal neurotransmitter released at the NMJ. The region opposite the synaptic bulb that ends in the muscle fiber is called the motor end plate, which has acetylcholine receptors. Within the...
01:20Myasthenia Gravis: Overview and Treatment
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...
01:28Disorders of the Skeletal Muscle
The clinical conditions affecting the skeletal muscle tissue are broadly categorized as musculoskeletal and neuromuscular disorders.
Musculoskeletal disorders
Musculoskeletal disorders involve injuries and conditions affecting the skeletal muscles and associated connective tissues. These disorders can arise from acute biomechanical stresses or chronic overuse and can occur across different age groups. Common injuries include sprains, fractures, and muscular strains, often resulting from...
Musculoskeletal disorders
Musculoskeletal disorders involve injuries and conditions affecting the skeletal muscles and associated connective tissues. These disorders can arise from acute biomechanical stresses or chronic overuse and can occur across different age groups. Common injuries include sprains, fractures, and muscular strains, often resulting from...
01:26Chemical Synapses
Chemical synapses are specialized sites between two neurons or between a neuron and a non-neuronal cell like a muscle, glandular or sensory cell.
Because chemical synapses depend on the release of neurotransmitter molecules from synaptic vesicles to pass on their signal, there is an approximately one millisecond delay between when the axon potential reaches the presynaptic terminal and when the neurotransmitter leads to opening of postsynaptic ion channels. Additionally, this signaling is...
Because chemical synapses depend on the release of neurotransmitter molecules from synaptic vesicles to pass on their signal, there is an approximately one millisecond delay between when the axon potential reaches the presynaptic terminal and when the neurotransmitter leads to opening of postsynaptic ion channels. Additionally, this signaling is...
01:26Chemical Synapses
Chemical synapses are specialized sites between two neurons or between a neuron and a non-neuronal cell like a muscle, glandular or sensory cell.
Because chemical synapses depend on the release of neurotransmitter molecules from synaptic vesicles to pass on their signal, there is an approximately one millisecond delay between when the axon potential reaches the presynaptic terminal and when the neurotransmitter leads to opening of postsynaptic ion channels. Additionally, this signaling is...
Because chemical synapses depend on the release of neurotransmitter molecules from synaptic vesicles to pass on their signal, there is an approximately one millisecond delay between when the axon potential reaches the presynaptic terminal and when the neurotransmitter leads to opening of postsynaptic ion channels. Additionally, this signaling is...